Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

205 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to compare the performance of two currently available influenza (flu) vaccines. This study will try and determine if the high dose flu vaccine provides protection that is the same or better than that of regular dose flu vaccine. Both the regular dose and the high dose flu vaccines are approved by the FDA for use in older adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

NCT02553343

Influenza

COMPLETED PHASE2

Study of Quadrivalent Influenza Vaccine Among Adults

NCT01218646

Influenza

COMPLETED PHASE3

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

NCT03282240

Influenza

COMPLETED PHASE3

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

NCT06641180

Influenza

COMPLETED PHASE3

Immune Response to High-Dose vs. Standard Dose Influenza Vaccine

NCT02297542

Elderly Immune System

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Influenza and pneumonia are the fifth leading cause of death in the United States, the leading cause of vaccine preventable death, and the leading cause of infection related deaths among nursing home residents(Nace, Drinka et al.2010). Each year, an estimated 36,000 individuals die from seasonal influenza and over 90% of these deaths occur among older adults, primarily the frail older adults residing in LTC settings(Fiore,Uyeki et al. 2010).Vaccination is the most effective means of preventing influenza (Nichol and Treanor 2006). Despite increasing success in immunizing LTC residents though, outbreaks continue to occur annually with case fatality rates ranging between 5-55% (Nace 2008). Older adults have a reduced response to influenza vaccination, in part due to age related immunosenescence (Keitel, Atmar et al. 1121; Skowronski, Tweed et al. 2008). It is widely recognized that more effective vaccine options are needed for frail older adults. One option is to increase the hemagglutinin (HA) dose in influenza vaccines in an effort to increase antibodies to hemagglutinin. To date, no studies have evaluated the effectiveness of the HDIV among LTC residents.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High Dose Inactivated Influenza Vaccine

For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin

Group Type ACTIVE_COMPARATOR

High Dose Inactivated Influenza Vaccine

Intervention Type BIOLOGICAL

0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin

Standard Dose Inactivated Influenza Vaccine

For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin

Group Type ACTIVE_COMPARATOR

Standard Dose Inactivated Influenza Vaccine

Intervention Type BIOLOGICAL

0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High Dose Inactivated Influenza Vaccine

0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin

Intervention Type BIOLOGICAL

Standard Dose Inactivated Influenza Vaccine

0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Residents of one of the participating LTC sites
* 65 years or older at the time of consent
* require assistance in two or more Instrumental Activities of Daily Living and/or one or more Activities of Daily Living as identified by facility staff

Exclusion Criteria

* Age less than 65 years
* Life expectancy less than 6 months
* History of allergic reaction to influenza vaccine, its components, or eggs
* History of severe allergic reaction to latex
* History of Guillian-Barre Syndrome
* Actively undergoing chemotherapy
* Actively undergoing radiation therapy
* Use of prednisone (or other steroid) at prednisone-equivalent dosages of 10mg or higher within the past 14 days
* Serious current immunosuppression or immunosuppression expected in the next 6 weeks
* Any condition that, in the opinion of the investigator,might interfere with the evaluation of study objectives

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes